- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00313807
Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage
CoNTRST - Contrast Nephropathy and Travasol for Renal Safety Trial: Intravenous Amino Acid Infusion for the Prevention of Contrast-mediated Acute Renal Failure Following Coronary Catheterization
Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk.
The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF.
We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure.
Retrospective studies have confirmed that at least 60% of contrast-associated nephropathy occurs in subjects with chronic renal failure. The incidence approaches 20% in those with a baseline creatinine greater than 198.2 μmol per liter (2.25 mg/dL). Diabetes, in the absence of renal insufficiency, does not appear to confer added risk; however diabetic patients with chronic renal failure are at highest risk. It is particularly this group that develops oliguric renal failure requiring temporary or permanent renal replacement therapy. In diabetic patients with mild to moderate renal failure, the incidence of contrast-associated nephropathy has been reported to be between 9% and 40% however a greater then 50% incidence has been noted in diabetic patients with more severely impaired renal function.
It is hypothesized that the renal toxicity of contrast medium is related to local vasoconstriction. We hypothesize that the protein-stimulated rise in effective RPF and GFR might counteract this intrarenal vasoconstriction and reduce the toxicity of contrast medium in high-risk patients with diabetes. We propose that an infusion of amino acids prior to the administration of contrast dye, will increase renal plasma flow and glomerular filtration rate by approximately 20% and hasten excretion of the contrast agent thereby protecting high-risk patients from contrast nephropathy.
This is a double-blind, randomized, placebo-controlled trial evaluating the effectiveness of an amino-acid infusion in addition to usual therapy (intravenous normal saline infusion) for the prevention of renal dysfunction following angiographic dye administration during coronary angiography in a high risk group of patients with chronic renal insufficiency.
Comparison: Primary and secondary outcomes in patients receiving intravenous amino acid infusion compared to placebo group receiving intravenous normal saline.
Tipo di studio
Fase
- Fase 2
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Greater then 18 years of age
- Referral for coronary angiography
- Type 1 or type 2 diabetic requiring insulin or oral hypoglycemic agents
- Stable serum creatinine concentration (140 to 300 μmol per liter for men or 125 to 300 μmol per liter for women or a creatinine clearance not greater than 60 ml/min (as calculated by Cockcroft-Gault equation)
- Non diabetic subjects with a stable serum creatinine concentration of 160 to 300 µmol per liter for men and 140 to 300 µmol per liter for women.
- Stable renal function defined as no documented rise or fall in serum creatinine by more then 44 umol/L in the preceding 2 weeks
Exclusion Criteria:
- Refusal or inability to give consent
- Pregnant
- Non-elective coronary angiography
- Recent administration (within 21 days) of iodinated intravenous contrast dye
- Recent administration (within 21 days) of non-steroidal anti-inflammatory drugs (excluding aspirin), aminoglycoside antibiotics or chemotherapeutic agents
- Severe/unstable diabetics requiring emergency room or inpatient therapy in the previous 21 days
- Compensated or decompensated hepatic failure
- Renal transplant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: 1
Intravenous saline infusion plus amino acid infusion
|
7% amino acid infusion
Altri nomi:
|
Comparatore placebo: 2
Intravenous saline infusion plus placebo infusion
|
0.9% Saline Infusion
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
to assess if the infusion of amino acids will help prevent kidney damage that can occur when angiographic dye is used to perform a cardiac catheterization
Lasso di tempo: Day 0 to Day 7
|
Day 0 to Day 7
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
the serum cystatin C level at 24 hours post procedure and 72 hours post procedure
Lasso di tempo: Day 0 to Day 3
|
Day 0 to Day 3
|
the number of patients with a peak increase in serum creatinine concentration of at least 44.1 umol/L between day 0 and day 3 (72 hours)
Lasso di tempo: Day 0 to Day 3
|
Day 0 to Day 3
|
the number of patients with a peak increase in serum creatinine concentration of at least 88.4 μmol per liter between day 0 and day 3 (72 hours) post-catheterization
Lasso di tempo: Day 0 to Day 3
|
Day 0 to Day 3
|
development of heart failure or myocardial infarction within 7 days
Lasso di tempo: 7 days
|
7 days
|
need for renal replacement therapy
Lasso di tempo: 7days
|
7days
|
death at 48 hours, 7 days, or 14 days post-catheterization
Lasso di tempo: 14 days
|
14 days
|
number of hospital days after catheterization
Lasso di tempo: 7 days
|
7 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Karen E Yeates, MD MPH, Assistant Professor, Queen's University - Division of Nephrology, Department of Medicine
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- contrst2006
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Insufficienza renale
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group BCompletatoCarcinoma a cellule renali a cellule chiare | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti, Canada, Porto Rico
-
National Cancer Institute (NCI)TerminatoCarcinoma a cellule renali a cellule chiare | Carcinoma a cellule renali metastatico | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio IV AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti
Prove cliniche su Amino Acid
-
Istituti Clinici Scientifici Maugeri SpAUniversity of PaviaCompletatoRiabilitazione dell'ictusItalia
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Non ancora reclutamentoNAFLD | Obesità adolescenziale | Steatosi epatica
-
Royal College of Surgeons, IrelandNualtraReclutamentoImpatto della valutazione e dell'intervento dietetico sui risultati nei pazienti con cirrosi epaticaSarcopenia | Cirrosi, FegatoIrlanda
-
Villa Garda HospitalUniversity of Milan; Università degli Studi di BresciaNon ancora reclutamento
-
McMaster UniversityAjinomoto USA, INC.CompletatoFenomeni psicologici: affaticamento centraleCanada
-
IBSA Farmaceutici Italia SrlAttivo, non reclutante
-
Amsterdam UMC, location VUmcIscrizione su invitoInsufficienza cardiaca con frazione di eiezione conservataOlanda
-
Princess Al-Johara Al-Ibrahim Cancer Research CenterCompletatoCarcinoma a cellule transizionali della vescicaArabia Saudita
-
Akdeniz UniversityReclutamentoDanno cerebrale | Postoperatorio | Chirurgia-complicanzeTacchino
-
Memorial Sloan Kettering Cancer CenterGE HealthcareCompletato